Supernus Pharmaceuticals Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Supernus Pharmaceuticals Inc Company

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Supernus Pharmaceuticals Inc Info



Ticker SymbolSUPN

Company nameSupernus Pharmaceuticals Inc

IPO dateDec 28, 2010

CEOMr. Jack A. Khattar

Number of employees674

Security typeOrdinary Share

Fiscal year-endDec 28

Address9715 Key West Avenue

CityROCKVILLE

Stock exchangeNASDAQ Global Market Consolidated

CountryUnited States of America

Postal code20850

Phone13018382500

Websitehttps://www.supernus.com

Ticker SymbolSUPN

IPO dateDec 28, 2010

CEOMr. Jack A. Khattar

Company Executives of Supernus Pharmaceuticals Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Jack A. Khattar

President, Chief Executive Officer, Secretary, Director

2.21M

+2.76%

Mr. Frederick M. Hudson, CPA

Independent Director

46.31K

-13.87%

Dr. Carrolee Barlow, M.D., Ph.D.

Independent Director

22.57K

--

Dr. Georges Gemayel, Ph.D.

Independent Director

18.68K

--

Mr. Frank Mottola

Chief Operating Officer, Chief Technology Officer

15.15K

--

Dr. Padmanabh P. Bhatt, Ph.D.

Senior Vice President - Intellectual Property, Chief Scientific Officer

13.37K

+5.27%

Dr. Jonathan Rubin, M.D.

Senior Vice President, Chief Medical Officer - Research and Development

10.67K

+10.74%

Mr. Timothy C. (Tim) Dec, CPA

Chief Financial Officer, Senior Vice President

901.00

-92.89%

Mr. Charles W. Newhall, III

Independent Chairman of the Board

--

Ms. Bethany L. Sensenig

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Jack A. Khattar

President, Chief Executive Officer, Secretary, Director

2.21M

+2.76%

Mr. Frederick M. Hudson, CPA

Independent Director

46.31K

-13.87%

Dr. Carrolee Barlow, M.D., Ph.D.

Independent Director

22.57K

--

Dr. Georges Gemayel, Ph.D.

Independent Director

18.68K

--

Mr. Frank Mottola

Chief Operating Officer, Chief Technology Officer

15.15K

--

Dr. Padmanabh P. Bhatt, Ph.D.

Senior Vice President - Intellectual Property, Chief Scientific Officer

13.37K

+5.27%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Net product sales-Qelbree

77.55M

46.87%

Net product sales - GOCOVRI

36.66M

22.16%

Net product sales-APOKYN

12.82M

7.75%

Net product sales- Oxtellar XR

11.64M

7.03%

Net product sales- Trokendi XR

11.19M

6.77%

Other

15.60M

9.43%

By RegionUSD

Name

Revenue

Proportion

United States

165.45M

100.00%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Net product sales-Qelbree

77.55M

46.87%

Net product sales - GOCOVRI

36.66M

22.16%

Net product sales-APOKYN

12.82M

7.75%

Net product sales- Oxtellar XR

11.64M

7.03%

Net product sales- Trokendi XR

11.19M

6.77%

Other

15.60M

9.43%

Shareholding Stats

Updated: Fri, Aug 15

Shareholders

Shareholder Types

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

13.97%

The Vanguard Group, Inc.

10.52%

Armistice Capital LLC

8.39%

Dimensional Fund Advisors, L.P.

5.27%

Macquarie Investment Management

4.82%

Other

57.03%

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

13.97%

The Vanguard Group, Inc.

10.52%

Armistice Capital LLC

8.39%

Dimensional Fund Advisors, L.P.

5.27%

Macquarie Investment Management

4.82%

Other

57.03%

Shareholder Types

Shareholders

Proportion

Investment Advisor

52.68%

Investment Advisor/Hedge Fund

29.42%

Hedge Fund

17.15%

Individual Investor

4.28%

Research Firm

2.30%

Pension Fund

1.59%

Venture Capital

1.47%

Bank and Trust

0.67%

Sovereign Wealth Fund

0.10%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

575

60.19M

104.97%

-3.36M

2025Q2

565

63.61M

113.46%

-2.51M

2025Q1

587

64.77M

115.71%

-2.86M

2024Q4

569

65.17M

116.92%

-2.59M

2024Q3

551

65.02M

117.72%

-2.14M

2024Q2

536

63.49M

115.33%

-2.27M

2024Q1

535

61.47M

111.83%

-3.83M

2023Q4

534

61.60M

112.54%

-3.30M

2023Q3

534

60.88M

111.42%

-4.46M

2023Q2

534

61.11M

111.93%

-1.60M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

BlackRock Institutional Trust Company, N.A.

8.01M

14.29%

-191.39K

-2.33%

Jun 30, 2025

The Vanguard Group, Inc.

6.19M

11.04%

+41.36K

+0.67%

Jun 30, 2025

Armistice Capital LLC

4.81M

8.58%

-384.00K

-7.39%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

3.02M

5.39%

+117.48K

+4.05%

Jun 30, 2025

Macquarie Investment Management

2.76M

4.93%

+62.46K

+2.31%

Jun 30, 2025

Khattar (Jack A)

2.15M

3.84%

+54.63K

+2.60%

Sep 30, 2025

State Street Investment Management (US)

2.21M

3.94%

+63.21K

+2.95%

Jun 30, 2025

Renaissance Technologies LLC

1.66M

2.95%

+69.60K

+4.39%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.40M

2.5%

+72.99K

+5.50%

Jun 30, 2025

Stephens Investment Management Group, LLC

1.58M

2.82%

-157.39K

-9.05%

Jun 30, 2025

Related ETFs



Updated: Thu, Nov 6

Name

Proportion

AdvisorShares Psychedelics ETF

5.4%

iShares Neuroscience and Healthcare ETF

4.31%

Invesco Pharmaceuticals ETF

2.88%

SPDR S&P Pharmaceuticals ETF

2.49%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.89%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.86%

Invesco S&P SmallCap Health Care ETF

1.7%

Lattice Hartford Multifactor Small Cap ETF

1.04%

iShares U.S. Pharmaceuticals ETF

0.99%

First Trust Multi-Manager Small Cap Opportunities ETF

0.59%

AdvisorShares Psychedelics ETF

Proportion5.4%

iShares Neuroscience and Healthcare ETF

Proportion4.31%

Invesco Pharmaceuticals ETF

Proportion2.88%

SPDR S&P Pharmaceuticals ETF

Proportion2.49%

Pacer US Small Cap Cash Cows Growth Leaders ETF

Proportion1.89%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proportion1.86%

Invesco S&P SmallCap Health Care ETF

Proportion1.7%

Lattice Hartford Multifactor Small Cap ETF

Proportion1.04%

iShares U.S. Pharmaceuticals ETF

Proportion0.99%

First Trust Multi-Manager Small Cap Opportunities ETF

Proportion0.59%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data